Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Lung adenocarcinoma accounts for ∼40% of lung cancers, the leading cause of cancer-related death worldwide, and current therapies provide only limited survival benefit. Approximately half of lung adenocarcinomas harbor mutations in TP53 (p53), making these mutants appealing targets for lung cancer therapy. As mutant p53 remains untargetable, mutant p53-dependent phenotypes represent alternative targeting opportunities, but the prevalence and therapeutic relevance of such effects (gain of function and dominant-negative activity) in lung adenocarcinoma are unclear. Through transcriptional and functional analysis of murine KrasG12D-p53null, -p53R172H (conformational), and -p53R270H (contact) mutant lung tumors, we identified genotype-independent and genotype-dependent therapeutic sensitivities. Unexpectedly, we found that wild-type p53 exerts a dominant tumor-suppressive effect on mutant tumors, as all genotypes were similarly sensitive to its restoration in vivo. These data show that the potential of p53 targeted therapies is comparable across all p53-deficient genotypes and may explain the high incidence of p53 loss of heterozygosity in mutant tumors. In contrast, mutant p53 gain of function and their associated vulnerabilities can vary according to mutation type. Notably, we identified a p53R270H-specific sensitivity to simvastatin in lung tumors, and the transcriptional signature that underlies this sensitivity was also present in human lung tumors, indicating that this therapeutic approach may be clinically relevant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · cited 1×
“5J), a group of drugs widely used in the clinic to lower de novo cholesterol biosynthesis and serum low-density lipoprotein cholesterol levels through the specific inhibition of HMG-CoA reductase (HMGCR) (Istvan and Deisenhofer 2001; Cholesterol Treatment Trialists Collaboration 2010).”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“Mutant p53 gain-of-function (GOF) phenotypes have been described in different tissues (Lang et al. 2004; Olive et al. 2004)”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 1×
“Mutant p53 gain-of-function (GOF) phenotypes have been described in different tissues (Lang et al. 2004; Olive et al. 2004)”
BackgroundCensus and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 7×
“…DEVELOPMENT 31:1339–1353 Published by Cold Spring Harbor Laboratory Press; ISSN 0890-9369/17; www.genesdev.org 1339 and helped uncover potential targetable vulnerabilities in p53 mutant breast cancer (Freed-Pastor et al. 2012) and pancreatic ductal adenocarcinoma (PDAC) (Weissmueller et al. 2014).”
BackgroundResultInfluentialCyclin G is a transcriptional target of the p53 tumor suppressor protein.
Okamoto, K., & Beach, D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06807.x · Cited by 455 · cited 2×
“p53 “canonical” targets were defined based on functional/expression studies (gene set enrichment analysis) (Okamoto and Beach 1994; Lehar et al. 1996; Utrera et al. 1998; Bieging et al. 2014) or ChIP data (http://chipTargeting p53 mutant lung tumors”
BackgroundMethodTranslating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · cited 3×
“MDM2/X inhibitors such as Nutlin-3 can activate wildtype p53 and have shown promising therapeutic effects (Vassilev et al. 2004; Cheok et al. 2011).”
BackgroundClassification of Proliferative Pulmonary Lesions of the Mouse
Nikitin, A. Y., Alcaraz, A., Anver, M. R., Bronson, R. T., Cardiff, R. D., Dixon, D., Fraire, A. E., Gabrielson, E. W., Gunning, W. T., Haines, D. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3376 · Cited by 334 · cited 1×
“Tumor grading was performed on hematoxylin and eosin (H&E)-stained sections according to Nikitin et al. (2004) and Junttila et al. (2010) (low grade: adenomas and grade 1 and 2 adenocarcinoma; high grade: grade 3 and 4 adenocarcinoma).”
MethodSchlereth, K., Heyl, C., Krampitz, A.-M., Mernberger, M., Finkernagel, F., Scharfe, M., Jarek, M., Leich, E., Rosenwald, A., & Stiewe, T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003726 · Cited by 87
Cited by
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
Friedmann Angeli, J. P., Krysko, D. V., & Conrad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0149-1 · Cited by 1,259
Lipid Peroxidation and Iron Metabolism: Two Corner Stones in the Homeostasis Control of Ferroptosis
Rochette, L., Dogon, G., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010449 · Cited by 919
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
González‐Gualda, E., Pàez‐Ribes, M., Lozano‐Torres, B., Macias, D., Wilson, J. R., González‐López, C., Ou, H., Mirón‐Barroso, S., Zhang, Z., Lérida‐Viso, A., et al. (2020) · Aging Cell · doi:10.1111/acel.13142 · Cited by 303
Self-citationStatins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196
“While wild-type p53 represses the mevalonate pathway (49), loss of p53 and certain gain-of-function p53 mutants have been shown to induce the expression of mevalonate pathway genes (41, 49, 50).”
Background
Metadata
- Authors
- Turrell, F. K., Kerr, E. M., Gao, M., Thorpe, H., Doherty, G. J., Cridge, J., Shorthouse, D., Speed, A., Samarajiwa, S., Hall, B. A., Griffiths, M., & Martins, C. P.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-07-01
- Volume
- 31
- Issue
- 13
- Pages
- 1339-1353
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2743915325
- Cited by
- 71
- References
- 12
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.